Thursday 10th September 2009
SESSION 5 - ROTAVIRUS & ROTAVIRUS VACCINES
Moderator: Roger Glass
(Fogarty International Centre, NIH, Bethesda, USA)
08:30-09:00
'Post-Licensure Monitoring of Rotavirus Vaccination in the United States'
U Parashar, P Haber, M Patel, C Panozzo, D Bartlett, J Tate, J Baggs,
D Payne, M Cortese, E Weintraub, H Clayton, A Curns, J Gentsch.
(CDC, Atlanta, USA)
09.00-09.30
‘Rotavirus genotype distribution in Australian children – what has happened during the first 18 months after introduction of RotaTeq™ and Rotarix™ ‘
C. Kirkwood, K. Boniface, G. Barnes and R. Bishop
(Royal Children’s Hospital, Parkville, Victoria, Australia)
09.30-09.50
'Post marketing surveillance for intussusception surveillance in Australia'
Julie Bines et al.
(The University of Melbourne, Royal Children's Hospital, Melbourne, Australia)
09.50-10.20
'Effectiveness of the monovalent G1P[8] human rotavirus vaccine in Recife, Brazil against severe diarrhoea caused by G2P[4] rotaviruses'
T Nakagomi, M Patel, O Nakagomi, FM Montenegro, EM Cermano,
NB Corriea, LE Cuevas, U Parashar, NA Cunliffe, JB Correia.
(Nagasaki University, Nagasaki, Japan)
10.20-10.50
'Intussusception and Kawasaki disease - are there still clouds in the skies of rotavirus vaccination?'
Timo Vesikari (University of Tampere, Tampere, Finland)
10.50-11.20 Coffee Break & Posters
11.20-11.40
'The pentavalent rotavirus vaccine, RotaTeq®: from development to licensure and beyond'
Max Ciarlet (Merck Research Laboratories, North Wales, Pennsylvania, USA)
11.40-12.00
'Summary of human rotavirus vaccine RotarixTM : Safety and efficacy trials'
Htay Htay Han (GSK Biologicals, Rixensart, Belgium)
12.00-12.20
'Rotavirus stimulates serotonin (5-HT) release from human enterochromaffin cells. A disease mechanism for vomiting'
Lennart Svensson, Claudia Istrate, Marie Hagbom, Vesa Loitto,
Karl-Erik Magnusson, Hakan Ahlman and Ove Lundgren
(University of Linkoping, Linkoping, Sweden)
12.20-14.00 Lunch Break & Posters
14.00-14.30
PLENARY LECTURE:
'The value of vaccination for the health and wealth of nations'
David Bloom (Harvard University, Boston, USA)
SESSION 6 - SHIGELLA
Moderator: Armelle Phalipon (Institut Pasteur, Paris, France)
14.30-14.50
'Shigella-ETEC vaccine trial update'
Karen L. Kotloff (University of Maryland, Baltimore, Maryland, USA)
14.50-15.10
'Live, attenuated Shigella dysenteriae 1 vaccine development'
Eileen M. Barry (University of Maryland, Baltimore, Maryland, USA)
15.10-15.30
'Cyclic occurrence of epidemics of Shigella sonnei shigellosis in Israel'
D. Cohen, R. Bassal, L. Valinski, V. Vasilev and M.S. Green
(Tel Aviv University, Tel Aviv, Israel)
15.30-15.50
'Oral live, attenuated Typhoid-Shigella multivalent vaccine development'
D.J. Kopecko, DeQi Xu, M. Osorio, J. Cisar, V. Truong and E. Patzer
(FDA-CBER, Bethesda, Maryland, USA)
15.50-16.10
'Safety, colonization, and immunogenicity of second generation live attenuated virG(icsA)-based Shigella vaccine strains following nasogastric inoculation of Rhesus Macaques'
Ryan T. Ranallo, Monica Dutta, Robert W. kaminski, Tara L. Boren, James E. Lee, Monica Buck, Todd Collins, Luis A. Lugo-Roman, Theron Gilliland Jr., Erica Jones, Shahida Baqar, Shoshana BarNoy, Akamol E. Suvarnapunya and Malabi M. Venkatesan
(Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)
16.10-16.40 Tea Break & Posters
16.40-17.00
'A novel approach to produce multivalent glycoconjugated vaccines against Shigellosis using recombinant bacterial cells that directly produce immunogenic bioconjugates'
Michael Wacker, Fabiana Fernandez, Michael Wetter, Michael Kowarik, Cyril Tanner, Stefanie Balada and Giampetro Corradin
(GlycoVaxyn AG, Schlieren, Switzerland)
17.00-17.20
'Shigella flexneri 2a Invaplex 50 intranasal vaccine phase 2b challenge study'
C. Harro et al. (Johns Hopkins University, Baltimore, Maryland, USA)
SESSION 7 - ENTERIC BACTERIAL/PARASITIC VACCINES
Moderator: Lou Bourgeois, (PATH, Washington DC)
17:20-17:40
‘Development of a low-dose challenge model for evaluation of vaccines for enterotoxigenic E. coli (ETEC) in volunteers’
Clayton Harro, Barbara DeNearing, Alicia Marcum, Andrea Feller,
Subhra Chakraborty, Barbora Hnizda, August Bourgeois, Richard Walker, Anna Lundgren , Ann-Mari Svennerholm, and David A. Sack.
(Johns Hopkins School of Public Health, Baltimore, Maryland, USA)
17.40-18.00
'Characterization of salmonella-specific CD4 T cells to oral infection or vaccination'
Stephen J. McSorley, Amanda Griffin, Seung-Joo Lee and
Joshua McCarra
(University of Minnesota Medical School, Minneapolis, Minnesota, USA)
18.00-18.20
'Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by IFN-©'
William A. Petri, Xiaoti Guo, Lisa barroso, Steven M. Becker,
David M. Lyerly, Thomas S. Vedvick, Steven G. Reed and Eric R. Houpt
(University of Virginia, Charlottesville, Virginia, USA)
18.20-18.40
'Campylobacter jejuni strain CG8421: A new model for the study of human campylobacteriosis'
B.D. Kirkpatrick, D. Tribble, S. Baqar, K. Pierce, M. Carmolli, C. Porter,
M. Darsley (University of Vermont, Burlington, Vermont, USA)
18.40-19.00
'Capsule-conjugate vaccines against Campylobacter jejuni diarrhea: estimates of required valencies'
Patricia Guerry, Frederic Poly, Oralek Serichantalergs, Piyarat Pootong, Panida Nobthai, Malla rao, Hind Shaheen, Remon Abu Elyazeed,
John Clemens, Shahida baqar, Eric Hall, Stephen J. Savarino and
Mario A. Monteiro.
(Naval Medical Research Center, Silver Spring, USA)
Free Evening for Delegates